论文部分内容阅读
目的:分析Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班对ST段抬高急性心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)中TIMI血流的影响。方法:选择急诊入院STEMI患者96例,分为试验组(盐酸替罗非班+PCI)54例和对照组(直接PCI)42例,收集所有病例临床和冠状动脉造影资料,观察PCI术前、术后TIMI血流情况。结果:试验组于术前应用盐酸替罗非班使PCI前梗死相关血管TIMI血流分级提高,试验组达1级血流者比例高于对照组(37%比9.5%,P<0.05),对照组完全闭塞者比例明显高于试验组(38.1%比7.4%,P<0.01)。结论:Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班可改善STEMI患者梗死相关血管TIMI血流。
Objective: To analyze the effect of Ⅱb / Ⅲa receptor antagonist tirofiban on TIMI flow in patients with ST-elevation acute myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Methods: A total of 96 STEMI patients were enrolled in this study. They were divided into trial group (tirofiban + PCI 54) and control group (direct PCI) 42 cases. Clinical data and coronary angiography were collected. Postoperative TIMI blood flow. Results: Tirofiban Hydrochloride Tirofiban Hydrochloride was used in the experimental group to improve the grade of infarction-related blood vessel TIMI in the experimental group. The proportion of grade 1 blood flow in the experimental group was higher than that of the control group (37% vs 9.5%, P <0.05) The proportion of complete occlusion in the control group was significantly higher than that in the experimental group (38.1% vs. 7.4%, P <0.01). Conclusion: Tirofiban hydrochloride, an antagonist of Ⅱb / Ⅲa, can improve infarction-related vascular TIMI flow in patients with STEMI.